Guardant Health, Inc.
Extracted from this filing and checked against the source text.
Guardant Health, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-14 meeting.
Proposal 2 in the Proxy Statement, a proposal to ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, was approved by the following vote: Votes For Votes Against Abstentions 84,048,978 26,878 32,392View on SEC.gov
Guardant Health, Inc. shareholders approved Advisory approval of named executive officer compensation at the 2023-06-14 meeting.
Proposal 3 in the Proxy Statement, a proposal to approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers, was approved by the following vote: Votes For Votes Against Abstentions Broker Non-Votes 66,909,185 10,481,515 178,806 6,538,742View on SEC.gov
Guardant Health, Inc. shareholders approved Election of Directors at the 2023-06-14 meeting.
All of the nominees for director listed in Proposal 1 in the Company’s Definitive Proxy Statement on Schedule 14A, as filed with the Securities and Exchange Commission on April 27, 2023 (the “ Proxy Statement ”), were elected to serve on the Company’s board of directors by the following vote: Name of Nominee Votes For Votes Withheld Broker Non-Votes Ian Clark 48,391,638 29,177,868 6,538,742 Meghan Joyce 57,913,641 19,655,865 6,538,742 Samir Kaul 76,695,081 874,425 6,538,742View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.